Company / Return on Equity (ROE)
Veracyte, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
5.1%
FY2025
5-year range
-7.1% / 5.1%
FY2021-FY2025
Trend
+147.3%
vs FY2024
Sector context
#69 of 147
Health Care
What the data says
At 5.1%, Veracyte, Inc.'s return on equity (roe) ranks #69 of 147 in the Health Care sector. Return on Equity (ROE) has fluctuated over the past 8 years, ranging from -28.8% in FY2018 to 5.1% in FY2025.
Based on SEC 10-K filings.
5.1% in FY2025 with a 5-year CAGR of +13.4%.
Improved from -7.1% to 5.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +8.5pp
- 5-Year Change
- +13.4pp
- 10-Year Change
- -
Sector benchmark
#69 of 147 in Health CareTop 47% of 147This company 5.1% Sector average -3.1%
▼
+262.5% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 147.3% year-over-year.
- Currently 8.2pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 5.1% | +147.3% |
| FY2024 | 2.1% | +128.8% |
| FY2023 | -7.1% | -109.7% |
| FY2022 | -3.4% | +50.7% |
| FY2021 | -6.9% | +16.9% |
| FY2020 | -8.3% | -57.6% |
| FY2019 | -5.3% | +81.8% |
| FY2018 | -28.8% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026